Efficacy of the novel RAS(ON) in KRASG12C mutant NSCLC - Haniel Araujo MD Anderson Cancer Center #Cancer #CancerDiscovery #NSCLC #OncoDaily #Oncology
OncoDaily’s Post
More Relevant Posts
-
The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology - Paolo Tarantino https://lnkd.in/gutH_7Kt #oncodaily #oncology #cancer #research #TRAIN3Trial #HER2Positive #BreastCancerResearch #BiomarkerDriven #OncologyInnovation #TheLancetOncology
Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
The results of this multi-center Phase III randomized trial by Steven Frank - MD Anderson Cancer Center American Society of Clinical Oncology (ASCO) #oncodaily #oncology #cancer #research #ASCO24 #ASCO2024
The results of this multi-center Phase III randomized trial by Steven Frank - MD Anderson Cancer Center - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
OncLive has an exciting video featuring Dr. Anne Chiang, discussing how the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC) has changed, thanks to data from the CASPIAN trial. The CASPIAN study investigated first-line treatments for ES-SCLC. Researchers compared different regimens, including durvalumab (an immunotherapy) combined with platinum/etoposide chemotherapy. The goal was to improve overall survival (OS) for patients facing this aggressive cancer. Be sure to watch the video! #cancer #oncology #lungcancerresearch https://lnkd.in/gEvqxrqz
Examining 3-Year Update Data from the CASPIAN Trial
onclive.com
To view or add a comment, sign in
-
A great summary by Priv.-Doz. Dr. med. Niklas Klümper Viktor Grünwald , Viktor Grünwald and team about the role of MMR/MSI - Emre Yekeduz American Society of Clinical Oncology (ASCO) #ASCO #Cancer #MMR #MSI #OncoDaily #Oncology
Emre Yekedüz: A great summary by Niklas Klümper, Viktor Grüenwald and team about the role of MMR/MSI - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Excited to share my latest conference abstract publication: "Irinotecan and S-1 Combination in Non-Small Cell Lung Cancer: Efficacy and Toxicity - A Systematic Review and Meta-Analysis." Explore the findings and insights here: https://lnkd.in/de4KbGzc. #LungCancerResearch #MedicalResearch #Oncology #MetaAnalysis
To view or add a comment, sign in
-
Our phase 2 trial of SG+Pembro in platinum-resistant IO-naive 2L setting - Petros Grivas ECOG-ACRIN Cancer Research Group #Cancer #CancerResearch #JournalOfClinicalOncology #OncoDaily #Oncology
Petros Grivas: Our phase 2 trial of SG+Pembro in platinum-resistant IO-naive 2L setting - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿" 🌟 Don't miss this episode of WND in Lung Cancer trial by Prof Johan Vansteenkiste and Prof Mariana Brandao on the LIBRETTO-431, investigating selpercatinib's efficacy in RET fusion-positive NSCLC patients. 👇 Watch all WND Lung videos - link in the comments! #MediMix #LungCancer #Immunotherapy #Oncology
To view or add a comment, sign in
-
The ArteraAI, Prostate Cancer Test can now inform active surveillance treatment decisions for low-risk patient - Andre Esteva, PhD PathNet National Comprehensive Cancer Network® (NCCN®) https://lnkd.in/eyu7BtEB #Cancer #OncoDaily #Oncology #PathNetLab #ProstateCancer
To view or add a comment, sign in
-
Here's a snippet from our latest episode of the Cancer Conversations series. In this episode, Niall Rochford, co-founder of Pancreatic Cancer Ireland, talks with Associate Professor in Translational Oncology in Trinity Translational Medicine Institute, Stephen Maher, about Pancreatic Cancer. They discuss the severity, causes, treatment and impact of this cancer and the research that is being carried out. Watch the full episode through the link below. 🔗 https://lnkd.in/eNmixXSt 🔗 Stephen Maher Niall Rochford #BreakthroughCancerResearch #MakeMoreSurvivors #CancerConversations #PancreaticCancer
To view or add a comment, sign in
-
🚨Highlights from ESMO 2024! Dr Laure-Anne Teuwen, medical oncologist at University Hospital Antwerp, shares key findings from metastatic breast cancer studies: - ABIGAIL: Abemaciclib plus endocrine therapy shows superior outcomes in HR+/HER2- breast cancer. - DETECT V:Examining whether chemotherapy can be omitted in HR+/HER2+ patients treated with an upfront endocrine therapy-based regimen - TIFFANY: A novel CDK4/6 inhibitor significantly extends PFS in HR+/HER2- breast cancer. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #BreastCancer #Oncology #CancerResearch #ClinicalTrials
To view or add a comment, sign in
25,910 followers